益丰药房: 益丰药房2024年年度股东会会议资料

Core Points - The annual shareholder meeting of Yifeng Pharmacy Chain Co., Ltd. is scheduled for May 29, 2025, in Changsha, Hunan Province [1] - The board of directors has prepared the 2024 annual report and submitted it for review at the shareholder meeting [4][20] - The company achieved a revenue of 24.06 billion yuan in 2024, representing an 8.26% increase year-on-year [6][25] - The net profit attributable to shareholders, excluding non-recurring gains and losses, increased by 9.40% compared to the previous year [6] - The company opened 2,512 new stores during the year, focusing on a strategy of regional concentration and steady expansion [5][10] Financial Performance - The company reported a total revenue of 24,062,154,701.73 yuan in 2024, up from 22,588,227,402.22 yuan in 2023, marking a growth of 6.53% [25] - The total assets of the company reached 27,974,736,950.35 yuan, a 15.90% increase from the previous year [25] - The operating profit also showed steady growth, with a net profit attributable to shareholders increasing to 980,443.25 million yuan [6][25] Board and Governance - The board of directors held 17 meetings during the reporting period, reviewing 68 proposals, including matters related to stock options and management appointments [6][7] - The audit committee of the board held 4 meetings, reviewing 16 proposals to ensure compliance with internal controls and external audits [6][7] - The independent directors actively participated in decision-making and provided constructive opinions to protect the interests of all shareholders [8] Strategic Initiatives - The company is focusing on digital transformation, supply chain optimization, and new retail models to enhance its competitive edge [9][10] - A comprehensive digital link from customers to products and operations is being established to shift the focus from product management to customer management [5][10] - The company aims to enhance its core competitiveness through brand image improvement, professional service capabilities, and differentiated product offerings [9][10] Market and Operational Insights - The retail segment remains the primary revenue source, accounting for 90.95% of total revenue, with a gross margin of 38.36% [27][28] - The company has seen growth across various product categories, with traditional Chinese medicine and non-pharmaceutical products also contributing positively [27][28] - The company is expanding its market presence in Central South, East China, and North China regions, implementing tailored strategies for each city [10]